These in vitro results suggest that the presence of Th9 cells could be a predictive marker for the use of anti–PD-1 therapy in bladder cancer patients, although this hypothesis should be tested in clinical or in vivo studies. This evidence concerns the gene PDCD1 and urinary bladder cancer.